Should you invest in Hims & Hers Health?
Hims & Hers Health is appealing to investors looking for growth in virtual healthcare. The company has expanded into high-demand areas like GLP-1 weight loss drugs, a market analysts expect to exceed $100 billion by the end of the decade. It also operates across large, underserved categories such as sexual health and mental health, giving it a broad total addressable market.
Growth has been strong. Subscribers increased 31% year over year in Q2 2025, and management expects $2.3 to $2.4 billion in revenue and up to $335 million in EBITDA for 2025. Its mix of subscription-based care and personalized treatments helps keep customers engaged.
That said, competition in telehealth is intense, and the stock is best suited for investors comfortable with growth-focused businesses rather than those seeking dividends or deep value.